485 related articles for article (PubMed ID: 18926947)
1. T2-weighted and T1-weighted dynamic superparamagnetic iron oxide (ferucarbotran) enhanced MRI of hepatocellular carcinoma and hyperplastic nodules.
Chen RC; Lii JM; Chou CT; Chang TA; Chen WT; Li CS; Tu HY
J Formos Med Assoc; 2008 Oct; 107(10):798-805. PubMed ID: 18926947
[TBL] [Abstract][Full Text] [Related]
2. Differentiation of well-differentiated hepatocellular carcinomas from other hepatocellular nodules in cirrhotic liver: value of SPIO-enhanced MR imaging at 3.0 Tesla.
Park HS; Lee JM; Kim SH; Chang S; Kim SJ; Han JK; Choi BI
J Magn Reson Imaging; 2009 Feb; 29(2):328-35. PubMed ID: 19161184
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging.
Lutz AM; Willmann JK; Goepfert K; Marincek B; Weishaupt D
Radiology; 2005 Nov; 237(2):520-8. PubMed ID: 16192317
[TBL] [Abstract][Full Text] [Related]
4. Characterization of focal hepatic lesions with ferumoxides-enhanced MR imaging: utility of T1-weighted spoiled gradient recalled echo images using different echo times.
Kim JH; Kim MJ; Suh SH; Chung JJ; Yoo HS; Lee JT
J Magn Reson Imaging; 2002 May; 15(5):573-83. PubMed ID: 11997899
[TBL] [Abstract][Full Text] [Related]
5. Detection of hepatocellular carcinoma arising in cirrhotic livers: comparison of gadolinium- and ferumoxides-enhanced MR imaging.
Tang Y; Yamashita Y; Arakawa A; Namimoto T; Mitsuzaki K; Abe Y; Katahira K; Takahashi M
AJR Am J Roentgenol; 1999 Jun; 172(6):1547-54. PubMed ID: 10350287
[TBL] [Abstract][Full Text] [Related]
6. [Dynamic and static MRI using superparamagnetic MRI contrast medium Resovist for visualizing primary and secondary liver tumors].
Vogl TJ; Schwarz W; Hammerstingl R; Kümmel S; Balzer JO; Mack MG; Diebold T; Balzer T; Shamsi K; Bechstein WO; Schrem H; Neuhaus P; Felix R
Rofo; 1997 Sep; 167(3):264-73. PubMed ID: 9376555
[TBL] [Abstract][Full Text] [Related]
7. Percentage of signal intensity loss for characterisation of focal liver lesions in patients with chronic liver disease using ferucarbotran-enhanced MRI.
Chou CT; Chen RC; Chen WT; Lii JM
Br J Radiol; 2010 Dec; 83(996):1023-8. PubMed ID: 20413445
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma: detection with gadolinium- and ferumoxides-enhanced MR imaging of the liver.
Pauleit D; Textor J; Bachmann R; Conrad R; Flacke S; Layer G; Kreft B; Schild H
Radiology; 2002 Jan; 222(1):73-80. PubMed ID: 11756708
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of small (Tonan T; Fujimoto K; Azuma S; Ono N; Matsushita S; Kojiro M; Hayabuchi N
Eur J Radiol; 2007 Oct; 64(1):133-9. PubMed ID: 17408900
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular lesions with increased iron uptake on superparamagnetic iron oxide-enhanced magnetic resonance imaging in cirrhosis or chronic hepatitis: comparison of four magnetic resonance sequences for lesion conspicuity.
Tanabe M; Ito K; Shimizu A; Fujita T; Onoda H; Yamatogi S; Washida Y; Matsunaga N
Magn Reson Imaging; 2009 Jul; 27(6):801-6. PubMed ID: 19144487
[TBL] [Abstract][Full Text] [Related]
11. [Use of SPIO-enhanced T1- and T2-weighted images for the differentiation of liver lesions: an ROC analysis].
Stroszczynski C; Gaffke G; Gretschel S; Rambow A; Jost D; Schlecht I; Schneider U; Schicke B; Hohenberger P; Gebauer B; Felix R
Rofo; 2003 Oct; 175(10):1368-75. PubMed ID: 14556106
[TBL] [Abstract][Full Text] [Related]
12. Effect of superparamagnetic iron oxide-enhanced MRI of the liver with hepatocellular carcinoma and hyperplastic nodule.
Takeshita K; Nagashima I; Frui S; Takada K; Yamauchi T; Harasawa A; Oba H; Kohtake H; Tanaka H; Suzuki S
J Comput Assist Tomogr; 2002; 26(3):451-5. PubMed ID: 12016379
[TBL] [Abstract][Full Text] [Related]
13. Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: importance of Kupffer cell number.
Lim JH; Choi D; Cho SK; Kim SH; Lee WJ; Lim HK; Park CK; Paik SW; Kim YI
Radiology; 2001 Sep; 220(3):669-76. PubMed ID: 11526265
[TBL] [Abstract][Full Text] [Related]
14. Characterization of focal liver lesions with superparamagnetic iron oxide-enhanced MR imaging: value of distributional phase T1-weighted imaging.
Lee JM; Kim CS; Youk JH; Lee MS
Korean J Radiol; 2003; 4(1):9-18. PubMed ID: 12679629
[TBL] [Abstract][Full Text] [Related]
15. Changes in signal-to-noise ratios and contrast-to-noise ratios of hypervascular hepatocellular carcinomas on ferucarbotran-enhanced dynamic MR imaging.
Park Y; Choi D; Kim SH; Kim SH; Kim MJ; Lee J; Lim JH; Lee WJ; Lim HK
Eur J Radiol; 2006 Sep; 59(3):424-31. PubMed ID: 16920312
[TBL] [Abstract][Full Text] [Related]
16. Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging.
Nasu K; Kuroki Y; Nawano S; Kuroki S; Tsukamoto T; Yamamoto S; Motoori K; Ueda T
Radiology; 2006 Apr; 239(1):122-30. PubMed ID: 16493012
[TBL] [Abstract][Full Text] [Related]
17. Tumor-liver contrast and subjective tumor conspicuity of respiratory-triggered T2-weighted fast spin-echo sequence compared with T2*-weighted gradient recalled-echo sequence for ferucarbotran-enhanced magnetic resonance imaging of hepatic malignant tumors.
Ishiyama K; Hashimoto M; Izumi J; Watarai J; Shibata S; Sato T; Yamamoto Y
J Magn Reson Imaging; 2008 Jun; 27(6):1322-6. PubMed ID: 18504744
[TBL] [Abstract][Full Text] [Related]
18. [Magnetic resonance imaging of hepatic focal lesions: dynamic contrastographic evaluation with gadolinium versus reticulo-endothelial hepato-specific contrast media].
Di Cesare E; Cariello G; Barile A; Sabatini M; Michelini O; Erriquez D; Masciocchi C
Radiol Med; 2000 Oct; 100(4):245-50. PubMed ID: 11155451
[TBL] [Abstract][Full Text] [Related]
19. Superparamagnetic iron oxide (SPIO)-enhanced liver MRI with ferucarbotran: efficacy for characterization of focal liver lesions.
Namkung S; Zech CJ; Helmberger T; Reiser MF; Schoenberg SO
J Magn Reson Imaging; 2007 Apr; 25(4):755-65. PubMed ID: 17335040
[TBL] [Abstract][Full Text] [Related]
20. Differentiation of liver hemangiomas from metastases and hepatocellular carcinoma at MR imaging enhanced with blood-pool contrast agent Code-7227.
Harisinghani MG; Saini S; Weissleder R; Halpern EF; Schima W; Rubin DL; Stillman AE; Sica GT; Small WC; Hahn PF
Radiology; 1997 Mar; 202(3):687-91. PubMed ID: 9051017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
